IBS clin­i­cal trial launch

Live pa­tients to test 4D Pharma’ s rev­o­lu­tion­ary Blau­tix treat­ment

The Press and Journal (Moray) - - BUSINESS - BY KEITH FIND­LAY

Life sciences firm 4D Pharma said yes­ter­day the world’s largest live bio­ther­a­peu­tic clin­i­cal trial was un­der way in a rev­o­lu­tion­ary ap­proach to treat­ing ir­ri­ta­ble bowel syn­drome (IBS).

The com­pany, which is head­quar­tered in Leeds but car­ries out re­search at Aberdeen Uni­ver­sity’s Forester­hill cam­pus, will give 500 pa­tients ei­ther Blau­tix – its po­ten­tially game-chang­ing treat­ment for IBS – or a placebo.

Tak­ing place at lo­ca­tions across the US and Euro­pean Union, the trial is the big­gest of its kind to date.

Live bio­ther­a­peu­tics such as Blau­tix are a rel­a­tively new group of medicines that use the bac­te­ria which colonise the hu­man body to tackle dis­ease.

An­nounc­ing the start of the phase two clin­i­cal trial stage for Blau­tix, 4D Pharma chief sci­en­tific of­fi­cer Alex Steven­son said: “We are de­lighted to have en­rolled the first pa­tient in this im­por­tant study, which brings us an­other step to­wards mak­ing Blau­tix avail­able for pa­tients.

“IBS re­mains an area of sig­nif­i­cant un­met need, with ex­ist­ing treat­ments lim­ited to symp­tom man­age­ment and many pa­tients strug­gling to achieve re­lief.

“By tar­get­ing the gut mi­cro­biome, Blau­tix tar­gets the un­der­ly­ing patho­phys­i­ol­ogy of IBS and has the po­ten­tial to fun­da­men­tally change the way pa­tients are treated.”

IBS is a func­tional bowel dis­or­der char­ac­terised by dis­com­fort, pain and changes in bowel habits, af­fect­ing as many as one in five peo­ple around the world.

4D Pharma has al­ready iden­ti­fied bac­te­ria that could pro­vide ef­fec­tive ther­a­pies for dis­eases such as cancer, asthma and autism as well as rheuma­toid arthri­tis and mul­ti­ple scle­ro­sis.

“The po­ten­tial to fun­da­men­tally change the way pa­tients are treated ”

THER­APY: In the trial IBS suf­fer­ers will be given the live bio­ther­a­peu­tic treat­ment Blau­tix which uses the body’s bac­te­ria to tackle dis­ease

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.